A transformation platform for medical research achievements will be established under a tripartite agreement signed by Guangdong Medical University (GDMU), China National Accord Medicines and Sinopharm Holding Guangzhou on Dec 26.

GDMU is a renowned institution of higher education specializing in medicine and health research and talent cultivation. The other two parties are subsidiaries of Sinopharm Group, an enterprise listed among the top 500 companies in the world.

In line with the agreement, the parties will integrate education, research, industry and sales in the medical industry by combining their strengths. Cooperation will cover talent training, scientific research and resource sharing.

Consensus has already been reached in terms of construction and operation of a clinical trial center as well as a platform for medical research achievement transformation and new product releases.

As Sinopharm plans to promote construction of hemodialysis centers in Guangdong province, GDMU will provide technical support utilizing its clinical experience in nephrosis. A modernized hemodialysis service network will be set up to the benefit of local residents.

According to Lin Min, president of China National Accord Medicines, the signing of the agreement not only resonates with the national strategy of Health China 2030, but assists the company in its expansion.